{"id":7402,"date":"2017-07-11T09:24:39","date_gmt":"2017-07-11T13:24:39","guid":{"rendered":"https:\/\/medicarereport.org\/?p=7402"},"modified":"2017-07-11T09:24:39","modified_gmt":"2017-07-11T13:24:39","slug":"what-to-watch-for-as-novartis-heads-to-the-fda-with-a-novel-cancer-therapy","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=7402","title":{"rendered":"What to watch for as Novartis heads to the FDA with a novel cancer therapy"},"content":{"rendered":"<p>(By Damian Garde and Adam Feurerstein for ST<em>A<\/em>T)<\/p>\n<p class=\"big-cap-wrap danger-zone\"><span class=\"big-cap\">T<\/span>he FDA has weighed in on Novartis\u2019 pioneering personalized cancer therapy, which looks almost certain to win approval. But the agency is wading into uncharted territory, bringing along a bevy a questions on manufacturing and long-term safety to a hotly anticipated public forum. <a href=\"https:\/\/www.statnews.com\/2017\/07\/10\/novartis-fda-cancer-car-t\/\">Continue reading article here&#8230;<\/a><\/p>\n<p class=\"big-cap-wrap danger-zone\"><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice<\/strong>: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Damian Garde and Adam Feurerstein for STAT) The FDA has weighed in on Novartis\u2019 pioneering personalized cancer therapy, which<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14,15],"tags":[],"class_list":["post-7402","post","type-post","status-publish","format-standard","hentry","category-medical-technology","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/7402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7402"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/7402\/revisions"}],"predecessor-version":[{"id":7403,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/7402\/revisions\/7403"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}